More data needed on Xeljanz, venous thromboembolism risk in ulcerative colitis

SAN ANTONIO — A post hoc analysis evaluating the safety of Xeljanz in ulcerative colitis revealed comparable incidence rates of pulmonary embolism and deep vein thrombosis in patients who did and did not receive the agent. However, researchers at the American College of Gastroenterology Annual Meeting stressed the need for more data to better understand the link between the agent and venous thromboembolic events after previous safety signals led to a change in prescribing guidelines in the United States.“On one level, these data are somewhat reassuring,” William J. Sandborn,Read More

Share on facebook
Share on twitter
Share on linkedin